Marrow Mesenchymal Stem Cell Transplantation For Acute Myocardial Infarction And Cx43 Experimental Study Of Changes

Background Acute myocardial infarction(AMI) is a disease that severely threatens people's lift, and represents the greatest cause of mortality in coronary heart disease(CHD). The cellular basis underlying cardiac dysfunction and arrhythmia after myocardial infarction(MI) is a loss of functional cardiomyocytes and a replacement of scar tissue. Adult cardiomyocytes have limited ability to regenerate. The endogenous regenerative capacity of these cells is inadequate to counterweigh the loss of cardiomyocytes that occurs with cardiac injury. The effectiveness of current medications remains limited. The ability to regenerate damaged myocardium presents a major challenge in the treatment of myocardial infarction. Therefore, the notion of replacing lost cardiomyocytes with exogenous stem cells capable of myocardial regeneration remains scientifically appealing and holds enormous therapeutic promise. Mesenchymal stem cells(MSCs)is one of the prospective candidates for cell transplantation therapy to regenerate infarcted myocardium. In recent years, MSCs have become a new focus of the cardiology and may be become the ideal therapeutic method to regenerate cardiomyocytes after the myocardial infarction. The underlying mechanisms, however, are incompletely understood and remain to be endlessly researched.Gap junctions(GJ) are specialized membrane structures consisting of arrays of intercellular channels that directly connect adjacent cells by providing chemical and electrical communication. They are composed of connexins(Cx). Cx43 is the major gap junction protein in the adult mammalian ventricle. In infarcted myocardium, the total amount of Cx43 was reduced and the distribution of Cx43...